Long-term safety and efficacy of tanezumab as treatment for chronic low back pain (NCT00924664)

Abstract

This randomized, parallel-group, multicenter study evaluated long-term safety and efficacy of tanezumab in patients with chronic low back pain (CLBP). Patients from the parent study (NCT00876187) were eligible for this safety extension study within 12 weeks after last dose of parent study medication or upon discontinuation due to lack of efficacy. Patients received 3 intravenous then 4 subcutaneous administrations of tanezumab 10mg (n=321) or 20mg (n=527) at 8-week intervals. Safety assessments included adverse event documentation, physical and neurological examinations, and laboratory tests.